SCHEMBL5541978

SCHEMBL5541978

O=COCc1cccc(-c2csnn2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.47
RAB9A P51151 4/20 0.47
MEN1 O00255 2/20 0.47
NPC1 O15118 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
POLB P06746 2/20 0.47
ALDH1A1 P00352 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
HPGD P15428 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MGLL Q99685 2/20 0.41
NOTUM Q6P988 1/20 0.37
MAPT P10636 3/20 0.36
GAA P10253 2/20 0.35
MAPK1 P28482 1/20 0.35
PTPN1 P18031 2/20 0.34
AKT1 P31749 1/20 0.34
PKM P14618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5540568 0.82 KMT2A (0.55) KMT2ARAB9AMEN1NPC1SMN1; SMN2
SCHEMBL5541973 0.81 KMT2A (0.47) KMT2ARAB9AMEN1NPC1SMN1; SMN2
SCHEMBL15677919 0.75 PRKCI (0.56) MGLLNOTUMAGXT
SCHEMBL5540736 0.74 AGXT (0.59) MGLLAGXT
SCHEMBL11394076 0.73 MAOB (0.39) PTPN1AGXT
SCHEMBL13788687 0.72 PRMT6 (0.59) KMT2ARAB9AMEN1NPC1SMN1; SMN2
SCHEMBL5544260 0.71 LMNA (0.47) KMT2ARAB9AMEN1NPC1SMN1; SMN2
SCHEMBL4750607 0.71 KMT2A (0.56) KMT2ARAB9AMEN1NPC1SMN1; SMN2
SCHEMBL12312574 0.69 MAP4K4 (0.48) KMT2ARAB9AMEN1NPC1SMN1; SMN2
SCHEMBL28107030 0.69 FFAR1 (0.50) AGXT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KMT2A 4267/4885RAB9A 2824/4885MEN1 3295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.